Ivermectin cream
DrugUp to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
NCT Number: NCT00994422
The purpose of this study is to compare the safety and efficacy of a 0.5% ivermectin cream to a placebo in subjects infested with head lice when used in an "at home" environment.
Looking for future studies?
Notify Me2 year and older
All sexes
Interventional
Phase 2
Cactus Kids Pediatrics, Yuma, Arizona, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
Time frame: Days 2 up to Day 15 post-treatment
Treatment success was defined as the absence of live lice and was determined by visual examination of hair and scalp by a trained evaluator.
Time frame: Day 1 up to Day 28 post-application
Time frame: Day 1 up to Day 15 post-application
Participants skin/scalp irritations were assessed before treatment (Day 1) and Post-treatment with either Ivermectin or placebo by a trained evaluator.
Severe scalp irritations were defined as follows:
Severe Pruritus - Nearly constant, frequent scratching, very bothersome; Severe Erythema - Large areas of the scalp are red; Severe Excoriation: Widespread breaking of the skin involving most of the scalp; Severe Pyoderma - Lesions with crusting or other evidence of infection, involving most of the scalp.
Topaz Pharmaceuticals Inc
Industry
A Double-Blind Randomized Study to Compare the Safety, Local Tolerability and Efficacy of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05565820
Ectoparasitic Infestations, Head Lice
Miami, Florida, United States
View Trial DetailsNCT06333054
Head Lice
Erfurt, Germany
View Trial DetailsNCT02974088
Ectoparasitic Infestations, Head Lice
Cambridge, United Kingdom
View Trial DetailsNCT03617926
Head Lice, Pediculosis Capitis
Miami, Florida, United States
View Trial Details